Private Investor Diary: Miserable May turns to Joyous June
In our latest monthly catch-up with top private investor John Rosier gives us his latest portfolio update, and how June has brought respite after a May to forget. Includes a look at the commodities balancing act between economic weakness and long-term supply deficits, the best ways to invest in healthcare, and assessing the AI threat.
You can read John’s Investment Chronicle in full by visiting https://www.jicuk.com/jic-portfolio and signing up for a two-week free trial.
01.08 Why the long-term case for commodities remains intact despite recent share price weakness across the sector as a result of current investor worries about the threat of recession.
3:27 The potential impact of the need for capital investment in new production on the current high cashflows and dividends of miners.
04:58 The investment case for () – an asthma diagnostics company - on of the JIC portfolio’s best performing investments in May.
07.52 () and investing in healthcare via the picks and shovels approach.
11:36 The importance of assessing the impact of AI on portfolio companies, positively and negatively, and the case for selling ().
13:50 The rationale behind new purchases including () and “quality compounder” RS Group (RS1), formerly Electrocomponents.
14:52 Translation specialist RWS () as an example of the difficulties in assessing AI’s impact.
18:20 Why John’s bought “boring” oversold () on the back of recent price weakness.
21:55 The tailwinds that have taken the portfolio back above £600k, including ’s () ongoing transformation into a cash generating machine.
23:50 () and its continuing earnings upgrade cycle and further buybacks.
24:50How the huge drop in the cost of shipping has helped Shoe Zone, and the potential read-across to ().
26.45 ’s () bounce back from its March low point.
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.